1328 related articles for article (PubMed ID: 8982753)
41. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
42. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
Olsson SE; Odlind V; Johansson ED; Nordström ML
Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
[TBL] [Abstract][Full Text] [Related]
43. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
44. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.
Mascarenhas L; van Beek A; Bennink HC; Newton J
Hum Reprod; 1998 Nov; 13(11):3057-60. PubMed ID: 9853856
[TBL] [Abstract][Full Text] [Related]
45. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
46. Norplant users with irregular bleeding. Ultrasonographic assessment and evaluation of serum concentrations of estradiol and progesterone.
Kaewrudee S; Taneepanichskul S
J Reprod Med; 2000 Dec; 45(12):983-6. PubMed ID: 11153258
[TBL] [Abstract][Full Text] [Related]
47. Immediate postpartum insertion of the norplant contraceptive device.
Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
[TBL] [Abstract][Full Text] [Related]
48. The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive.
Affandi B; Cekan SZ; Boonkasemsanti W; Samil RS; Diczfalusy E
Contraception; 1987 Feb; 35(2):135-45. PubMed ID: 3109803
[TBL] [Abstract][Full Text] [Related]
49. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.
Csemiczky G; Dieben T; Coeling Bennink HJ; Landgren BM
Contraception; 1996 Dec; 54(6):333-8. PubMed ID: 8968661
[TBL] [Abstract][Full Text] [Related]
50. New concepts in contraception: Norplant subdermal implant.
Lynn MM; Holdcroft C
Nurse Pract; 1992 Mar; 17(3):85-9. PubMed ID: 1565306
[TBL] [Abstract][Full Text] [Related]
51. Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding.
Rogers PA; Lederman F; Plunkett D; Affandi B
Hum Reprod; 2000 Aug; 15 Suppl 3():152-61. PubMed ID: 11041231
[TBL] [Abstract][Full Text] [Related]
52. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
53. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
[TBL] [Abstract][Full Text] [Related]
54. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
[TBL] [Abstract][Full Text] [Related]
56. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
57. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
Sivin I; Lähteenmäki P; Mishell DR; Alvarez F; Diaz S; Ranta S; Grozinger C; Lacarra M; Brache V; Pavez M; Nash H; Stern J
Contraception; 1997 Nov; 56(5):317-21. PubMed ID: 9437561
[TBL] [Abstract][Full Text] [Related]
58. Endometrial effects of levonorgestrel and estradiol: A Scanning electron microscopic study of the luminal epithelium.
Nilsson O; Englund D; Weiner E; Victor A
Contraception; 1980 Jul; 22(1):71-83. PubMed ID: 6774851
[TBL] [Abstract][Full Text] [Related]
59. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)--an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research.
Datey S; Gaur LN; Saxena BN
Contraception; 1995 Mar; 51(3):155-65. PubMed ID: 7621684
[TBL] [Abstract][Full Text] [Related]
60. Subdermal contraceptive implants.
Peralta O; Diaz S; Croxatto H
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
